1 h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases

A compound of Formula (I-1) or (I-2):

• or a pharmaceutically acceptable salt thereof, wherein:
• Q1 and Q2 each independently represent C or N;
• X1 is N, N—RX1, or C—RX1;
• X2 is S, N—RX2 or C—RX2;
• X3 is N, O, S or C—RX3, provided when X2 is S, then X3 cannot be S or O;
• X4 is N or C—RX4;
• X5 is C—RX5;
• X6 is N or C—RX6;
• Y1 is N or C—RY1;
• Y2 is N—RY2 or C—RY2;
• Y3 is N or C—RY3;
• Y4 is N or C—RY4;
• Y5 is C—RY5;
• Y6 is C—RY6;
• RX1, RX3, RX4 and RX6 are each independently selected from H, halo, —CN, —NR1aR1b, —OR1c, C1-4 alkyl and C1-4 haloalkyl;
• RX2 and RX5 are each independently selected from H, halo, CN, —NR1aR1b, —OR1c, C1-6 alkyl, C3-8 cycloalkyl and RS, wherein C1-6 alkyl and C3-8 cycloalkyl represented by RX2 and RX5 are each optionally substituted with one or more R8;
• RY1, RY3, RY4 and RY6 are each independently selected from H, halo, —CN, —NR1aR1b, —OR1c, C1-4 alkyl and C1-4 haloalkyl;
• RY2 and RY5 are each independently selected from H, halo, —CN, —NR1aR1b, —OR1c, C1-6 alkyl, C3-8 cycloalkyl and RS, wherein C1-6 alkyl and C3-8 cycloalkyl represented by RY2 and RY5 are each optionally substituted with one or more R8;
• RS is independently selected from C6-10 aryl, 4 to 7 membered monocyclic heterocyclyl and 5 to 10 membered heteroaryl, wherein the C6-10 aryl, 4 to 7 membered monocyclic heterocyclyl and 5 to 10 membered heteroaryl represented by RS are each optionally substituted with one or more R7;
• R1, R2, R3, R4, R5 and R6, are each independently selected from H, halo, —CN, —NR1aR1b, —OR1c, C1-6 alkyl, C3-8 cycloalkyl, C6-10 aryl, 4 to 10 membered heterocycloalkyl and 5 to 10 membered heteroaryl, wherein the C1-6 alkyl, C3-8 cycloalkyl, C6-10 aryl, 4 to 10 membered heterocycloalkyl and 5 to 10 membered heteroaryl represented by R1, R2, R3, R4, R5 and R6 are each optionally substituted with one or more substituents independently selected from halo, —CN, —NR1aR1b, —OR1c, C1-6 alkyl and C3-8 cycloalkyl;
• R7 is independently selected from halo, —CN, —NR1aR1b, —NR1aC(O)R1d, —OR1c, —C(O)OR1c, —C(O)NR1aR1b, —SO2R1c, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4 to 7 membered monocyclic heterocycloalkyl, 7 to 10 membered bicyclic heterocycloalkyl, and 5 to 6 membered heteroaryl;
• wherein the C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4 to 7 membered monocyclic heterocycloalkyl, 7 to 10 membered bicyclic heterocycloalkyl, and 5 to 6 membered heteroaryl represented by R7 are each optionally substituted with one or more R7a;
• or alternatively two of R7, taken together with their intervening atoms, for a 3- to 7-membered monocyclic heterocyclyl that is optionally substituted by one or two substituents independently selected from C1-6 alkyl and oxo (═O);
• R7a, for each occurrence, is independently selected from halo, —CN, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, —NR1aR1b, —OR1c and 4 to 6 membered monocyclic heterocycloalkyl, wherein the C1-4 alkyl, C3-6 cycloalkyl and 4 to 6 membered monocyclic heterocycloalkyl are each optionally substituted with one or more substituents independently selected from C1-3alkyl, —OR1c, CN and halo;
• R8, for each occurrence, is independently halo, —CN, —NR1aR1b, —OR1c, —C(O)OR1c, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4 to 7 membered monocyclic heterocycloalkyl, or 5 to 6 membered heteroaryl;
• wherein the C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4 to 7 membered monocyclic heterocycloalkyl, and 5 to 6 membered heteroaryl represented by R1 are each optionally substituted with one or more substituents independently selected from halo, C1-4 alkyl, C1-4haloalkyl, C3-6 cycloalkyl, —NR1aR1b, —OR1c and 4 to 6 membered monocyclic heterocycloalkyl;
• R1a and R1b are each independently H or C1-4 alkyl;
• R1c is H, C1-4 alkyl or C1-4 haloalkyl;
• R1d is C1-4 alkyl or —OR1e;
• R1e is C1-4 alkyl, and
• wherein at least one of RX1, RX2, RX3, RX4, RX5 and RX6 is not H, and at least one of RY1, RY2, RY3, RY4, RY5 and RY6 is not H.